BIVI BioVie Inc.
$1.93▲ +1.05%
Healthcare
Other
After hours
$1.93▲ +0.00%
Sep 11, 7:30 PM ET
Volume 170.5K
Avg Volume (10D) 527.4K
Key Metrics & Fundamentals
Market Cap
$16.31M
P/E Ratio
–
Div Yield
–%
52W Range
0.82 - 3.79
% vs 50 MA
11.75%
% vs 200 MA
28.15%
RSI-14
52.1
MACD Histogram
-0.0200
Beta (1Y vs SPY)
1.98
Free Cash Flow
-$4.12M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$5.64M
COGS
–
Operating Exp
$5.72M
Operating Income
-$5.72M
EBIT
-$5.72M
Pretax Income
-$5.65M
Net Income
-$5.65M
Price & Volume History
Loading chart…
Recent News
Dow closes sharply lower as oil surge fuels inflation fears
Proactive · Sep 8, 2026 2:10 PM
BioVie advances Parkinson’s Phase 3 development program with FDA engagement
Proactive · Sep 8, 2026 1:52 PM
BioVie Announces Update to Parkinson’s Phase 3 Development Program
GlobeNewswire · Sep 8, 2026 11:30 AM
BioVie completes final patient visit in Phase 2 Long COVID trial
Proactive · Aug 31, 2026 1:05 PM
New to The Street Broadcasts Today Across Bloomberg Television U.S., Latin America and MENA at 6:30 PM ET
ACCESS Newswire · Aug 22, 2026 2:40 PM
Top Premarket Gainers
MT Newswires · Aug 19, 2026 11:11 AM
First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
ACCESS Newswire · Aug 14, 2026 1:00 PM
BC-Most Active Stocks
Associated Press · Aug 12, 2026 2:30 PM
Parkinson's drug developers are betting big on inflammation
Proactive · Aug 7, 2026 5:13 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See BIVI's money flow as a full page
Social Sentiment
Avg +0.80 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.